Buller Kathryn M, Carty Michelle L, Reinebrant Hanna E, Wixey Julie A
Perinatal Research Centre, University of Queensland Centre for Clinical Research, Herston, Queensland, Australia.
J Neurosci Res. 2009 Feb 15;87(3):599-608. doi: 10.1002/jnr.21890.
Minocycline is a second-generation tetracycline and a potential neuroprotective intervention following brain injury. However, despite the recognized beneficial effects of minocycline in a multitude of adult disease states, the clinical application of minocycline in neonates is contentious. Tetracyclines, as a class, are not usually administered to neonates, but there is compelling evidence that minocycline reduces brain injury after neonatal hypoxic-ischemic brain injury. This Review focuses on the evidence for minocycline use in neonates by considering aspects of pharmacology, drug regimens, functional outcomes, and mechanisms of action.
米诺环素是第二代四环素类药物，是脑损伤后一种潜在的神经保护干预措施。然而，尽管米诺环素在多种成人疾病状态下已被认可具有有益作用，但米诺环素在新生儿中的临床应用仍存在争议。四环素类药物通常不用于新生儿，但有确凿证据表明米诺环素可减轻新生儿缺氧缺血性脑损伤后的脑损伤。本综述通过考虑药理学、给药方案、功能结局和作用机制等方面，重点关注米诺环素在新生儿中应用的证据。
